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Abstract 
Background: Malaria programmes use Plasmodium falciparum histidine-rich protein-2 (PfHRP2) based rapid diagnos-
tic tests (RDTs) for malaria diagnosis. The deletion of this target antigen could potentially lead to misdiagnosis, delayed 
treatment and continuation of active transmission.
Methods: Plasmodium falciparum isolates (n = 1162) collected in Southern Mozambique were assessed by RDTs, 
microscopy and/or 18SrRNA qPCR. pfhrp2 and pfhrp3 deletions were investigated in isolates from individuals who 
were negative by RDT but positive by microscopy and/or qPCR (n = 69) using gene-specific PCRs, with kelch13 PCR as 
the parasite DNA control.
Results: Lack of pfhrp2 PCR amplification was observed in one of the 69 isolates subjected to molecular analysis 
[1.45% (95% CI 0.3–7.8%)].
Conclusions: The low prevalence of pfhrp2 deletions suggests that RDTs will detect the vast majority of the P. falcipa-
rum infections. Nevertheless, active surveillance for changing deletion frequencies is required.
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Background
Malarial parasites exhibit striking genetic plasticity that 
allows their rapid adaption to new drugs [1] and detec-
tion methods [2, 3]. This adaptability of the parasite 
endangers preventive and therapeutic measures against 
malaria, as the success of control programmes largely 
relies on early diagnosis and effective treatment. Rapid 
diagnostic tests (RDTs) are commonly used in malaria 
case management and elimination programmes, particu-
larly in remote areas where facilities for microscopy are 
not available [4].
Plasmodium falciparum histidine-rich protein-2 
(PfHRP2), together with Plasmodium lactate dehy-
drogenase and aldolase, are the key target antigens in 
commercially available RDTs [5]. Evidence from South 
America, India and Africa [2, 3] suggest that “deletion” 
of the target epitope within the parasite PfHRP2 antigen 
could adversely impact the life of an affected individual 
as a consequence of delayed or no treatment. Besides 
pfhrp2, pfhrp3 also affects the performance of RDT, as 
it has sequence homology with the pfhrp2 and can be 
detected by the monoclonal antibodies used against 
PfHRP2 in RDTs [6].
With increasing false negative RDT reports in African 
countries, WHO has considered the need of rigorous 
monitoring of malaria parasites that lack the pfhrp2 gene 
[2, 3, 7]. RDTs were introduced in Mozambique in 2007 
and national wide use started in 2010 [8]. However, there 
is no information available about the extent of pfhrp2 
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and pfhrp3 deletions in P. falciparum parasites circulat-
ing in Mozambique.  In this context, this study aimed to 
assess the presence of pfhrp2 and pfhrp3 deletions in P. 




Between 2010 and 2016, a total of 9124 blood samples 
were collected onto filter papers during cross-sectional 
studies conducted at the beginning (November) or end 
(May) of the malaria season in Southern Mozambique 
(Manhiça and Magude; Table 1). In Mozambique, a peak 
in transmission is usually seen during the rainy sea-
son, from November to April. Transmission intensity in 
southern Mozambique is generally low, although areas of 
high transmission may still be observed [9].
Malaria diagnosis was conducted using microscopy, 
HRP2-based RDT and qPCR; or only RDTs and qPCRs. 
The inclusion criteria for the deletion analysis were: 
1) a negative HRP2-based RDT (SD BIOLINE Malaria 
Antigen P. f—05FK50) but positive by microscopy and 
qPCR (18S rRNA) or 2) a negative HRP2-based RDT but 
positive qPCR (18S rRNA) if microscopy was not per-
formed. First, a nested PCR targeting single copy k13 
gene  (nPCRk13) was performed to verify the presence 
of parasite DNA in the sample [10]. Second, pfhrp2 and 
pfhrp3 genes were amplified using standard primers as 
described elsewhere [5, 11]. Finally, pfhrp2 and pfhrp3 
deletions were concluded if kelch13 gene PCR was posi-
tive, but PCRs for pfhrp2 and pfhrp3 failed to amplify 
the respective gene. The laboratory-adapted culture lines 
3D7 as a positive control for both pfhrp2 and pfhrp3, 
and HB3 and DD2 as negative controls for pfhrp3 and 
pfhrp2, respectively, were amplified simultaneously. The 
National Mozambican Ethics Review Committee and 
the Hospital Clínic of Barcelona Ethics Review Commit-
tee approved the collection of samples and molecular 
analysis. Informed consent and permission (in the case of 
children under 18 years of age) were also obtained from 
each participant or a parent/legal guardian during the 
cross-sectional studies.
Microscopy
Thin and thick blood smears were air-dried, stained with 
Giemsa and examined using a light microscope fitted 
with a 100 × oil immersion lens and a 10 × eyepiece to 
quantify parasitaemia in the Centro de Investigação em 
Saúde de Manhiça (CISM) laboratory [9]. Slides were 
read twice by two different qualified microscopists, and if 
there was discordance in the results, a third reading was 
performed by an additional microscopist.
Rapid diagnostic test
A trained laboratory technician collected approximately 
10 μL of blood from an individual by finger-prick to per-
form an RDT. The PfHRP2-based RDT (SD BIOLINE 
Malaria Antigen P. f—05FK50) was used as per the manu-
facturer’s instructions.
DNA extraction and Plasmodium falciparum detection 
by real time PCR (qPCR)
DNA was extracted from a half of the filter paper (What-
man,  903TM), containing a 25  μL blood drop by using 
QIAamp DNA Mini kit (Qiagen). The ABI PRISM 7500 
HT Real-Time System (Applied Biosystems) was used to 
amplify purified parasite DNA templates, using a previ-
ously described method [12, 13]. Parasitaemia in the clin-
ical samples was quantified by extrapolation against the 
standard curve prepared from an in vitro culture of 3D7 
strain.
kelch13 nested PCR  (nPCRk13)
Purified DNA templates were amplified using 2720 Ther-
mal Cycler (Applied Biosystems) following a previously 
described method for the kelch13 gene [10].
Table 1 P. falciparum isolates collected during cross-sectionals with diagnostic results
Years Place Samples collected P. falciparum positive samples RDT negative, microscopy 
and qPCR positives samples
RDT negative and only qPCR 
positives samples
2010 Manhiça 969 105 1 –
2011 Manhiça 842 138 3 –
2012 Manhiça 924 116 3 –
2013 Manhiça 829 166 8 –
2014 Manhiça 908 211 7 –
2015 Manhiça 770 93 9 –
2015 Magude 981 101 7 –
2015 Magude 1322 174 – 125
2016 Magude 1579 58 1 –
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pfhrp2 and pfhrp3 PCRs
Samples with intact parasite DNA confirmed by  nPCRk13 
were used for further amplification of region cover-
ing exon 1 and 2, as well as exon 2 of pfhrp2 and pfhrp3 
genes [5, 11], following previously described methods 
with minor changes. These changes include the use of 
1× HOT FirePol Master Mix, annealing temperatures 
of 63  °C of 1  min for across regions of exon 1 and 2 of 
pfhrp2 gene and 60  °C of 1  min for exon 2 amplifica-
tion for both pfhrp2 and pfhrp3 genes. PCR products 
were visualized using 2% agarose (Invitrogen) and a UV 
trans-illuminator.
Results
Among the 9124 blood samples collected from partici-
pants in cross-sectional studies conducted in Southern 
Mozambique between 2010 and 2016, 1162 were P. fal-
ciparum positive by qPCR and/or by microscopy and 
RDTs. Among these 1162 P. falciparum isolates, 164 
samples were found eligible for the pfhrp2 and pfhrp3 
deletion analysis based on a RDT negative, micros-
copy positive and qPCR positive results (MO+/RDT−/
qPCR+; n = 39), or an RDT negative and qPCR positive 
result (RDT−/qPCR+ ; n = 125). Filter papers and corre-
sponding DNAs were available for 155 (95%) of these 164 
P. falciparum isolates. Among these, 70 (45%) were posi-
tive by  nPCRK13 (849  bp amplicon size; Fig.  1). Median 
qPCR parasite densities of the P. falciparum isolates 
that were negative by nPCR targeting kelch13 gene was 
2.17  parasites/µL (interquartile range 1.2–4.4  parasites/
µL).
69 samples were analysed for pfhrp2 and pfhrp3 dele-
tions, as one DNA sample was not enough for the analysis 
(Fig. 1). Parasite densities in these samples ranged from 
the 3 to 330,214 parasites/µL by qPCR (Table 2). The lab-
oratory 3D7 strain returned all the expected PCR prod-
ucts of pfhrp2 (exon 1–2 = 303 bp and exon 2 = 816 bp) 
and pfhrp3 (exon 1–2 = 301 bp and exon 2 = 719 bp). As 
expected, laboratory strains DD2 and HB3 lacked pfhrp2 
and pfhrp3 amplifications respectively (Fig. 2).
Fig. 1 Schematic representation of sample selection for pfhrp2 and pfhrp3 deletion analysis
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Table 2 Parasite densities (parasites/µL of blood), age, sex and year of sample collection of the samples included in the 
study
Years Place Parasitemia by microscopy Parasitemia by qPCR Sex Age (in years)
2010 Manhiça 1670 3858.5 Male 4
2013 Manhiça 56 33.5 Male 12
2013 Manhiça 546 600.3 Male 2
2013 Manhiça 143603 25250 Male 3
2013 Manhiça 203 1500 Male 14
2013 Manhiça 39 13.2 Female 24
2014 Manhiça 232 996.6 Male 4
2014 Manhiça 44594 23469.6 Female 15
2014 Manhiça 140814 84817 Female 3
2014 Manhiça 5721 3827.8 Female 7
2014 Manhiça 52 657.5 Female 3
2015 Manhiça 386 167.58659 Female 14
2015 Manhiça 1657 3407.6235 Female 8
2015 Manhiça 100 98.169426 Female 2
2015 Manhiça 325 156.13457 Male 2
2015 Manhiça 51 32.917961 Male 11
2015 Manhiça 99 108.99004 Male 17
2015 Manhiça 5648 1463.4641 Female NA
2015 Magude 3610 1610.6819 Female 4
2015 Magude 2950.5 676.75568 Male 9
2015 Magude 303.5 224.56026 Female 50
2015 Magude 928.5 384.57782 Male 2
2015 Magude 2637 95.924171 Female 11
2015 Magude NA 14.8498 Male 7
2015 Magude NA 2.44336 Female 10
2015 Magude NA 27.025 Male NA
2015 Magude NA 2.70269 Female 15
2015 Magude NA 20.8876 Female 47
2015 Magude NA 330214 Female 3
2015 Magude NA 99.4996 Female 4
2015 Magude NA 14.9045 Female 12
2015 Magude NA 8.46764 Female 7
2015 Magude NA 9.3634 Male 3
2015 Magude NA 69.8859 Male 43
2015 Magude NA 4.21137 Female 17
2015 Magude NA 4.75359 Female 9
2015 Magude NA 314.461 Male 4
2015 Magude NA 104.915 Male 19
2015 Magude NA 25.1698 Female 11
2015 Magude NA 27.3208 Male 28
2015 Magude NA 20.9188 Female NA
2015 Magude NA 1184.68 Male 15
2015 Magude NA 4.68228 Female 9
2015 Magude NA 612.026 Female 12
2015 Magude NA 182.307 Female 7
2015 Magude NA 61.8145 Female 5
2015 Magude NA 6.33165 Female 2
2015 Magude NA 50.2857 Female 40
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No amplification was noticed in negative controls (with 
water and human genomic DNA), which confirms the P. 
falciparum specificity of all the primer sets used in this 
study. Expected PCR products were observed upon the 
amplification of regions across exon 1 and exon 2, as well 
as exon 2 of pfhrp2 and pfhrp3 genes in all the samples 
except one sample (H1.3). PCR amplification of region 
covering pfhrp2 exon 1 and exon 2, as well as exon 2 was 
not observed in isolate H1.3 (Fig. 2a), while obtaining a 
positive amplification product for kelch13 gene. This lack 
of amplification was confirmed in a second and inde-
pendent PCR test. The microscopy and qPCR parasite 
density of sample H1.3 were 2950.5 and 676.75 parasites/
µL, respectively. Upon case investigation, this sample 
was found to correspond to a 30 months old male child 
from Magude who reported previous episodes of fever 
(during last 30 days), lived in a fumigated household and 
slept under a bed net the night before the sample was col-
lected. Apart from this, varying pfhrp2 and pfhrp3 exon 2 
PCR products lengths (600–1000 bp) were also observed 
in the analysed samples.
Discussion
This study provides the first evidence of pfhrp2 deletion 
in P. falciparum isolates circulating in Southern Mozam-
bique. The prevalence of 1.45% (95% CI 0.3–7.8%) 
pfhrp2 deletion among analyzed samples is low as 
compared to the prevalence observed in other malaria 
endemic countries such as India (2.4%), Senegal (2.4%), 
Mali (5%) and Ghana (30.3%) [14–17]. As per WHO 
guidelines, 5% prevalence of pfhrp2 deletion has been 
considered as a minimum threshold to change the type 
of RDTs [3]. Therefore, PfHRP2-based RDTs are likely 
to detect the vast majority of the malaria parasites in 
southern Mozambique, but careful periodic monitoring 
for changes in deletion frequencies may be required to 
identify cases such as the single mutant detected in this 
study.
Previous reports have shown that pfhrp3 deletion 
could be an early warning signal for pfhrp2 deletion [11]. 
However, the pfhrp3 deletion has not been observed in 
the present study. Since only blood spots on filter paper 
were available in this study, plasma PfHRP2 protein lev-
els or RNA based assays for the same sample could not 
be performed. However, a number of independent pfhrp2 
PCR based investigation was done to confirm the lack of 
pfhrp2 gene in the P. falciparum isolate. Moreover, as sig-
nificant amount of P. falciparum isolates (n = 164) were 
detected by real time PCR but not by nested PCR, given 
lower sensitivity of the latter [18], and consequently were 
not eligible for hrp2/hrp3 assessment. Finally, the vary-
ing length of exon 2 of pfhrp2 and pfhrp3 PCR products 
NA not available
Table 2 continued
Years Place Parasitemia by microscopy Parasitemia by qPCR Sex Age (in years)
2015 Magude NA 90.4941 Male 1
2015 Magude NA 14.7296 Male 3
2015 Magude NA 539.879 Female 35
2015 Magude NA 8.85961 Male 12
2015 Magude NA 231.339 Female 8
2015 Magude NA 19.9863 Male 15
2015 Magude NA 55.4191 Female 2
2015 Magude NA 73.8065 Male 12
2015 Magude NA 24.4031 Female 29
2015 Magude NA 419.439 Female 27
2015 Magude NA 158.95 Male 12
2015 Magude NA 6.46944 Female 45
2015 Magude NA 9.88753 Female 40
2015 Magude NA 2.68125 Male 18
2015 Magude NA 78.1784 Female 13
2015 Magude NA 20.7993 Male 15
2015 Magude NA 576.566 Female 11
2015 Magude NA 54.7864 Male 9
2015 Magude NA 19.1635 Female 35
2015 Magude NA 491.664 Male 45
2016 Magude 609 645.284 Male 31
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indicates the presence of different numbers of previously 
identified amino acid repeats [5].
According to 2016 WHO world malaria day fact sheet, 
the use of RDT has significantly increased globally from 
46 million sold in 2008 to 314 million in 2014. In 2014, 
53% of global RDTs (P. falciparum-specific tests) were 
delivered to African countries [3]. The excessive use of 
PfHRP2 based RDTs might enhance the selection of P. 
falciparum isolates with pfhrp2 deletion, especially in 
endemic areas where pfhrp2 deletion is present. Thus, it 
is important to monitor the presence of parasites with 
pfhrp2 and pfhrp3 deletions to avoid false negative results 
by RDT. Limitation of the study is that the sample’s mate-
rial was not available for amplification of flanking genes 
of pfhrp2 and pfhrp3 genes.
Conclusions
The low prevalence of pfhrp2 deletions suggests that 
RDTs will detect the vast majority of the P. falciparum 
infections in Mozambique. However, active surveillance 
to detect increases in pfhrp2 deletion frequencies is 
required towards the common goal to eliminate malaria.
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